Dermatology News

The FDA has approved the seventh biosimilar to adalimumab, adalimumab-aqvh, for all eligible indications of the biologic product, the latest in an increasingly crowded biosimilar logjam set to release in 2023.

Patients with self-reported elevated spine symptoms in psoriatic arthritis, with or without a diagnosis of axial disease, had worse quality of life and disease activity overall versus patients without axial manifestations, according to data.

A 12-year-old boy presents to his primary care provider with a painful lesion on the medial aspect of his right proximal thumb.

The FDA has approved Rinvoq, a 15-mg, once-daily oral JAK inhibitor, for the treatment of adults with active psoriatic arthritis who have had an inadequate response, or intolerance to, TNF inhibitors, according to an AbbVie press release.

In this episode, Joel M. Gelfand, MD, MSCE, and Leonard H. Calabrese, DO, are joined by Paul E. Sax, MD, as they discuss advances in the outpatient management of COVID-19 and emerging information about the omicron variant.

Guselkumab is associated with durable improvements in multiple psoriatic disease domains through 2 years, with no new safety findings, in patents who are biologic-naïve, according to data published in Arthritis & Rheumatology.

Once-daily topical tapinarof cream reduced the severity of plaque psoriasis, as well as improved patient-reported outcomes, according to two phase 3 clinical trials.

A university psoriatic arthritis center focusing on close collaboration between rheumatologists and dermatologists helped significantly decrease time to diagnosis, according to data published in BMC Rheumatology.

A 9-year-old boy from southern California was taken to his primary care provider’s office for evaluation of an unusual sore on his forearm.

Secukinumab is efficacious in children and adolescents with psoriatic arthritis and enthesitis-related arthritis, resulting in a significantly longer time to flare versus placebo, according to data presented at ACR Convergence 2021.